Search research articles
Contact Us
Filters
Showing results (351-360 of 449) with videos related to
Page
of 45
Sort By:
Cells
|
March 10, 2022
Illuminating Host-Parasite Interaction at the Cellular and Subcellular Levels with Infrared Microspectroscopy
Hany M Elsheikha, Alaa T Al-Sandaqchi, Mohammad S R Harun, et al.
Cerebral Cortex (New York, N.Y. : 1991)
|
June 27, 2019
PTEN Activity Defines an Axis for Plasticity at Cortico-Amygdala Synapses and Influences Social Behavior
Cristina Sánchez-Puelles, María Calleja-Felipe, Alberto Ouro, et al.
European Psychiatry : the Journal of the Association of European Psychiatrists
|
July 21, 2023
The future of diagnosis in clinical neurosciences: Comparing multiple sclerosis and schizophrenia
Błażej Misiak, Jerzy Samochowiec, Krzysztof Kowalski, et al.
The Lancet. Microbe
|
July 5, 2021
Paucity and discordance of neutralising antibody responses to SARS-CoV-2 VOCs in vaccinated immunodeficient patients and health-care workers in the UK
Angalee Nadesalingam, Diego Cantoni, David A Wells, et al.
Cerebral Cortex (New York, N.Y. : 1991)
|
September 28, 2019
Corrigendum to: -PTEN activity defines an axis for plasticity at cortico-amygdala synapses and influences social behavior
Cristina Sánchez-Puelles, María Calleja-Felipe, Alberto Ouro, et al.
Gut
|
August 5, 2020
Major GI bleeding in older persons using aspirin: incidence and risk factors in the ASPREE randomised controlled trial
Suzanne E Mahady, Karen L Margolis, Andrew Chan, et al.
Neurology and Therapy
|
July 4, 2025
Summary of Research: Blood Biomarker Dynamics in People with Relapsing Multiple Sclerosis Treated with Cladribine Tablets: Results of the 2-Year MAGNIFY-MS Study
Heinz Wiendl, Frederik Barkhof, Xavier Montalban, et al.
Frontiers in Immunology
|
February 18, 2025
Blood biomarker dynamics in people with relapsing multiple sclerosis treated with cladribine tablets: results of the 2-year MAGNIFY-MS study
Heinz Wiendl, Frederik Barkhof, Xavier Montalban, et al.
Frontiers in Immunology
|
March 20, 2025
Corrigendum: Blood biomarker dynamics in people with relapsing multiple sclerosis treated with cladribine tablets: results of the 2-year MAGNIFY-MS study
Heinz Wiendl, Frederik Barkhof, Xavier Montalban, et al.
Neurodegenerative Disease Management
|
April 7, 2026
A plain language summary on clinical and mechanistic effects of cladribine in relapsing multiple sclerosis: 2-year results from the MAGNIFY-MS study
Klaus Schmierer, Heinz Wiendl, Frederik Barkhof, et al.
Page
of 45
Search research articles
Search
Showing results (351-360 of 449) with videos related to
Sort By:
Page
of 45
Cells
|
March 10, 2022
Illuminating Host-Parasite Interaction at the Cellular and Subcellular Levels with Infrared Microspectroscopy
Hany M Elsheikha, Alaa T Al-Sandaqchi, Mohammad S R Harun, et al.
Cerebral Cortex (New York, N.Y. : 1991)
|
June 27, 2019
PTEN Activity Defines an Axis for Plasticity at Cortico-Amygdala Synapses and Influences Social Behavior
Cristina Sánchez-Puelles, María Calleja-Felipe, Alberto Ouro, et al.
European Psychiatry : the Journal of the Association of European Psychiatrists
|
July 21, 2023
The future of diagnosis in clinical neurosciences: Comparing multiple sclerosis and schizophrenia
Błażej Misiak, Jerzy Samochowiec, Krzysztof Kowalski, et al.
The Lancet. Microbe
|
July 5, 2021
Paucity and discordance of neutralising antibody responses to SARS-CoV-2 VOCs in vaccinated immunodeficient patients and health-care workers in the UK
Angalee Nadesalingam, Diego Cantoni, David A Wells, et al.
Cerebral Cortex (New York, N.Y. : 1991)
|
September 28, 2019
Corrigendum to: -PTEN activity defines an axis for plasticity at cortico-amygdala synapses and influences social behavior
Cristina Sánchez-Puelles, María Calleja-Felipe, Alberto Ouro, et al.
Gut
|
August 5, 2020
Major GI bleeding in older persons using aspirin: incidence and risk factors in the ASPREE randomised controlled trial
Suzanne E Mahady, Karen L Margolis, Andrew Chan, et al.
Neurology and Therapy
|
July 4, 2025
Summary of Research: Blood Biomarker Dynamics in People with Relapsing Multiple Sclerosis Treated with Cladribine Tablets: Results of the 2-Year MAGNIFY-MS Study
Heinz Wiendl, Frederik Barkhof, Xavier Montalban, et al.
Frontiers in Immunology
|
February 18, 2025
Blood biomarker dynamics in people with relapsing multiple sclerosis treated with cladribine tablets: results of the 2-year MAGNIFY-MS study
Heinz Wiendl, Frederik Barkhof, Xavier Montalban, et al.
Frontiers in Immunology
|
March 20, 2025
Corrigendum: Blood biomarker dynamics in people with relapsing multiple sclerosis treated with cladribine tablets: results of the 2-year MAGNIFY-MS study
Heinz Wiendl, Frederik Barkhof, Xavier Montalban, et al.
Neurodegenerative Disease Management
|
April 7, 2026
A plain language summary on clinical and mechanistic effects of cladribine in relapsing multiple sclerosis: 2-year results from the MAGNIFY-MS study
Klaus Schmierer, Heinz Wiendl, Frederik Barkhof, et al.
Page
of 45